GTX

GTx, Inc., headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel hormonal therapeutics for cancer and serious conditions related to men’s health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial evaluating ACAPODENE® 80 mg for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial evaluating ACAPODENE® 20 mg for the prevention of prostate cancer in high risk men with the premalignant lesion known as high grade prostatic intraepithelial neoplasia. GTx has licensed to Ipsen Group exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing ostarine, a first-in-class selective androgen receptor modulator, or SARM. GTx believes that ostarine has the potential to treat a variety of indications, including cancer cachexia, end stage renal disease muscle wasting, frailty and osteoporosis. GTx plans to initiate a Phase IIb ostarine clinical trial for cancer cachexia by the summer of 2007. GTx also has an extensive preclinical pipeline generated from a world-class discovery program which includes the specific product candidates prostarine, a SARM for benign prostatic hyperplasia, and andromustine, an anticancer product candidate, for hormone refractory prostate cancer.

Contact Details: 3 North Dunlap Street Memphis Tennessee 38163 United States of America Tel: 901.523.9700 Ext.170 Fax: 901.523.9772 Email: investor.relations@gtxinc.com WWW: www.gtxinc.com/

Loading...

Recent Publications by GTX:
Steroidal Androgens and Nonsteroidal, Tissue Selective Androgen Receptor Modulators (SARM), S-22, Regulate Androgen Receptor Function Through Distinct Genomic and Non-Genomic Signaling Pathways. Androgen Receptor (AR) ligands are important for the development and...	20th September, 2008	Preclinical Research and Development, GTx, Inc., 3 North Dunlap, Memphis,	Mol Endocrinol. 2008 Sep 18. DOI Direct Link
Preclinical Characterization of a (S)-N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception. The pharmacologic effects of...	6th September, 2008	Division of Pharmaceutics, College of Pharmacy, The Ohio State University,	Endocrinology. 2008 Sep 4. DOI Direct Link
Vitamin D3-24-hydroxylase (CYP24) as a potential target for intervention with diabetic and nondiabetic nephropathy. The pharmacologic effects of...	16th March, 2007	GTX Pharmaceuticals, Griobenzell, Germany.	Clin Lab. 2007;53(1-2):85-8.
Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Several methods to assess genotoxicity of physical and chemical agents...	27th January, 2007	Cytomation GTX Inc., Fort Collins, CO, USA.	Mutat Res. 2006 Dec 1;602(1-2):14-25. Epub 2006 Oct 11. DOI Direct Link
Rhabdovirus assembly and budding. Rhabdoviruses are a diverse, widely-distributed group of enveloped viruses...	1st March, 2005	GTx Inc., 3 N. Dunlap, Van Vleet Research Building, Memphis, TN 38163,	Virus Res. 2004 Dec;106(2):117-32. DOI Direct Link
→View more GTX research publications.

BioNews Results for GTX:
GTx to Present at the UBS Global Life Sciences Conference	Pharma Live:  Sep 18 2008 5:30PM Matching: gtx
GTx to Present at the UBS Global Life Sciences Conference	DiGiTAL50:  Sep 18 2008 7:26PM Matching: gtx
GTX INC EPS Estimated At -1.55: Current Recommendation is Market Outperform	Calibre Macro World:  Sep 18 2008 10:07PM Matching: gtx
GTx Presents Bone Turnover Marker Data and Additional PSA Progression Safety Analysis for Toremifene 80 mg Pha	Pharma Live:  Sep 17 2008 12:01AM Matching: gtx
GTx cites favorable trend in prostate cancer study	Interactive Investor International:  Sep 16 2008 5:17PM Matching: gtx
Promote your company here: BioNewsCast - Press Release Distribution	→View more GTX news.

GTX Patents:
US Patent No.	Title
7016536	Method and apparatus for automatic cleaning and enhancing of scanned documents
6873436	Image processing device and recording medium
4989257	Method and apparatus for generating size and orientation invariant shape features
4975975	Hierarchical parametric apparatus and method for recognizing drawn characters
4949388	Method and apparatus for recognition of graphic symbols
→View more GTX patents.

GTX (GTXI) Financial information Links from Barchart
GTXI Quote from from Barchart.com
GTXI Chart from from Barchart.com
GTXI Profile from from Barchart.com
GTXI Opinion from from Barchart.com
→View more GTX finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 416 times since April 2007, the link to the organisation's website has been followed 61 times

Recent Search Terms used to find this page: GTX pharma | ostarine september | GTx Inc SARM male contraceptive SEC | ostarine propanamide | acapodene gtx | androgen receptor GTX | gtx pharma | GTx Biopharm | t | Prostarine gtx | .

Search for more companies in Memphis

Search for more companies in Tennessee

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for GTX